MariMed (MRMD) Q2 2026: 280E Tax Relief Was $786K, Unpaid Tax Now $31.5M
Listen to this report
The tax relief arrived. It was worth $786,000. The bank started collecting anyway.
RoboSystems coverage update · Cannabis · Source filing: Q2 FY2026 10-Q (quarter ended June 30, 2026, filed August 13, 2026). All figures verified live from the SEC XBRL graph via RoboSystems unless attributed otherwise. Not investment advice. No price target.
1. The Hook
Last quarter we covered MariMed $MRMD at about seven cents and left one specific thing on the watch list: the first benefit from April's medical-only rescheduling should show up in the Q2 FY2026 tax line. It did. It was $786,000. In the same quarter the company was charged $2.0 million of income tax on a $1.6 million pretax loss, an effective rate of negative 130 percent, and its unpaid tax balance climbed to $31.5 million against $8.4 million of cash.
That is the answer to the question we asked, and it is a smaller answer than the sector's headlines imply. But the Q2 filing contains something we did not have last quarter, and it is the more important find. Buried in the liquidity section is a First Amendment to MariMed's bank loan, signed effective December 31, 2025 "in connection with" the federal tax lien. Under it, starting January 2026, MariMed must deposit $100,000 every month into a non-interest-bearing account held by its lender until the full disputed tax amount is on deposit. MariMed has spent three years declining to pay the IRS. Its bank has now started collecting the money instead. The float was never free. Somebody just put a price on it.
2. Company Snapshot
MariMed is a vertically integrated multi-state cannabis operator headquartered in Norwood, Massachusetts, trading over the counter as MRMD. It runs 13 Thrive dispensaries across five states and seven cultivation and production facilities totalling about 526,000 square feet across nine states, and it sells branded products, Betty's Eddies, Nature's Heritage, Vibations, Bubby's Baked and InHouse, into a wholesale network the company says reached 85 percent of available storefronts on a trailing twelve month basis. Revenue splits roughly 55 percent retail and 44 percent wholesale. This update is built on the Q2 FY2026 10-Q filed August 13, 2026, alongside the FY2025 10-K that anchored our initiating coverage. The stock closed at $0.0858 on August 21, 2026, a $34.6 million market cap on 403.0 million shares, inside a 52-week range of $0.061 to $0.230.
3. The Financial Story
The top line set a record while the earnings power shrank. Q2 revenue of $41.9 million was the highest quarter in company history, up 6.1 percent year over year, with retail up 4.0 percent and wholesale up 8.1 percent. Growth came from Delaware and Maryland, and to a lesser extent Ohio, partly offset by declines in Massachusetts and parts of Illinois. Underneath it, adjusted EBITDA fell to $3.9 million from $4.8 million, down 17.5 percent. Gross margin compressed 160 basis points to 38.7 percent. Operating income dropped 59 percent to $418,000. This is MariMed's 26th consecutive quarter of positive adjusted EBITDA, a genuinely rare streak in this sector, and the streak is thinning: record revenue is now buying less profit than the same business bought a year ago.
The tax line is where the story lives, and the distinction that matters is charged versus paid. Those are two different numbers and conflating them inverts the whole thesis. Look at what MariMed has been charged and what it has actually written checks for:
| Period | Pretax income | Income tax charged | Income taxes paid (cash) | Accrued tax on balance sheet |
|---|---|---|---|---|
| FY2022 | $19.5M | $5.9M | $14.6M | $11.5M |
| FY2023 | $(6.6)M | $9.4M | $6.4M | $14.4M |
| FY2024 | $(4.3)M | $8.2M | $0.7M | $21.9M |
| FY2025 | $(10.9)M | $3.6M | $(0.7)M refund | $27.0M |
| H1 FY2026 | $(2.7)M | $4.7M | $0.1M | $31.5M |
Read the last two columns together. Over the last ten reported quarters, MariMed has been charged $16.4 million of income tax and has paid $130,000 of cash tax, net of a refund. That is eight tenths of one percent of what it was charged. In 2022, when it was profitable, it paid $14.6 million in a single year. It is not a company being drained by 280E cash payments. It is a company being charged an impossible bill, booking it in full, and declining to settle it. The unpaid balance has gone from $11.5 million to $31.5 million in three and a half years, a 2.7 times increase, and it is classified as a current liability. As recently as the day this quarter was reported, when the stock touched $0.064, that unpaid tax bill was larger than MariMed's entire market capitalization.
The mechanism behind the refusal is worth naming, because it is not passive. The IRS filed a lien against MariMed in June 2025 for roughly $6 million of 2023 taxes. It filed a second lien in February 2026 against First State Compassion Center, the Delaware business MariMed bought in March 2025, for roughly $1 million covering 2023 and 2024. MariMed is disputing both through Collection Due Process hearings, and the filing states the operative fact plainly: "While the matters are pending, IRS enforcement is generally stayed." The CDP hearing is the pause button. It is what converts a tax bill into working capital.
And that is exactly what the lender noticed. MariMed's balance sheet rests on a $58.7 million loan from Needham Bank, signed November 2023 at 8.43 percent, secured by first mortgages on its Maryland and Massachusetts real estate. Effective December 31, 2025, in connection with the tax lien, the borrowers signed a First Amendment requiring $100,000 per month into a non-interest-bearing cash collateral reserve account held by the lender, until the full amount of the disputed taxes is on deposit, pledged as additional collateral and available to pay those taxes. Do the arithmetic on the filing's own terms: against roughly $6 million of disputed 2023 tax, at $100,000 a month, the account takes 60 months to fill. That is $1.2 million a year of cash flow going into a dead account, against $3.2 million of operating cash flow in the first half. Roughly 19 cents of every operating cash flow dollar is now being set aside for a tax MariMed says it does not owe. The company still generated more cash than last year, $3.2 million versus $1.6 million in H1, and it has no near-term maturity wall, only $1.6 million due in the rest of 2026 and $3.7 million in 2027 against $78.8 million of total debt. But the escrow is a standing claim on the free cash flow that made the story interesting in the first place.
4. Catalyst Scenarios: How the Math Changes
Medical relief is real, and it is small. The April 23, 2026 Department of Justice final order moved FDA-approved cannabis drugs and cannabis on a qualifying state medical list into Schedule III, taking that business out of 280E. MariMed recorded the impact in Q2 and quantified it: a $786,000 reduction in income tax expense. Without it, the quarter's provision would have been about $2.8 million rather than $2.0 million, so the relief cut the quarter's tax charge by roughly 28 percent. It did not make the charge go away, because MariMed is mostly an adult-use business and adult-use is still Schedule I. There is also a live dependency: MariMed submitted DEA registration applications for certain medical operations on June 25, 2026, and its own release says DEA registration is a requirement to qualify for the Schedule III protections. The benefit is booked; the registration is pending.
The broad switch is still the entire trade. This has not changed since our initiating coverage, and the Q2 numbers sharpen it. If 280E came off adult-use income too, MariMed's tax charge does not shrink, it reverses: a company with a $2.7 million half-year pretax loss and no 280E would book a tax benefit of roughly $0.7 million rather than a $4.7 million charge. That is a swing of about $5.3 million per half year, roughly $10.7 million annualized, on a company with a $34.6 million market cap. And it would put the $31.5 million accrued liability into play, because the argument for writing it back gets far stronger than the argument for paying it.
Consolidation is the other exit, and the price of it is now visible. MariMed remains a plausible target: durable branded products, positive EBITDA, owned real estate, limited-license positions in Delaware and Maryland. What Q2 clarifies is what a buyer is actually buying. Enterprise value is about $105 million at the August 21 price. Add the $31.5 million of accrued tax as the claim it legally is and the number a buyer underwrites is closer to $136 million. The equity is a $34.6 million sliver on top of that, which is why this stock moves 8 percent down on a print and 11 percent up a week later.
5. Valuation: What It's Worth If It's a Normal Business
Start with the trailing twelve months through June 30: revenue of $163.8 million and adjusted EBITDA of $17.1 million. At the August 21 close, MariMed trades at about 0.64 times EV to revenue and 6.1 times EV to adjusted EBITDA. Against the Tier 2 comp set in our sector table, priced May 29, 2026, at an average 1.2 times revenue and 8.9 times EBITDA, that looks like a 31 percent discount on EBITDA.
It mostly is not a discount. It is the tax bill. Treat the $31.5 million of accrued, current, unpaid income tax as the claim it is, and enterprise value goes to about $136 million, EV to EBITDA goes to 8.0 times, and the discount to the Tier 2 average narrows from 31 percent to about 10 percent. On sales the discount survives, 0.83 times against 1.2 times. That is the cleanest way to say what the market is doing with this name: it is not mispricing a good business, it is pricing a good business plus a tax liability, and most of the apparent cheapness is the liability.
| Lens | Assumption | Implied EV | Implied equity |
|---|---|---|---|
| Today, August 21, 2026 | $0.0858 per share | $105M | $34.6M |
| Today, tax counted as debt | Add $31.5M accrued tax | $136M | $34.6M |
| CPG re-rating, tax written back | 10x to 14x on $17.1M EBITDA | $171M to $239M | $101M to $169M |
| CPG re-rating, tax paid in full | Same, less the $31.5M | $171M to $239M | $69M to $137M |
Implied value under stated assumptions. Not a price target, not a recommendation. The re-rating rows assume broad rescheduling removes 280E and MariMed's EBITDA earns a consumer-products multiple, neither of which has happened.
The shape is what matters. Because roughly $70 million of net debt sits under a $34.6 million equity, every dollar of enterprise-value change is amplified two to three times at the stock. The bull outcome is a two to five times equity, depending entirely on whether the $31.5 million is written back or written a check for. The bear outcome uses the same leverage in reverse. Nothing in this quarter moved that dial much; what moved is that the escrow now drains 19 percent of operating cash flow while everyone waits.
6. Risks and Open Questions
The liabilities are concrete and the timeline is not. The tax overhang grew again, to $31.5 million, roughly 3.7 times cash and 91 percent of the market cap, with two IRS liens filed and both under CDP dispute; an adverse resolution is not fundable out of $8.4 million of cash and $3.2 million of half-year operating cash flow. The escrow is a live drain at $1.2 million a year for as long as five years, and it is senior in practice because the lender holds the account. Operations are softening underneath a record top line: adjusted EBITDA down 17.5 percent, gross margin down 160 basis points, bad debt expense doubled, Massachusetts and parts of Illinois declining. The catalyst is partial and conditional: medical-only relief was worth $786,000 in its first quarter of application and is not yet a confirmed run rate, adult-use remains Schedule I, and MariMed's medical benefit depends on DEA registrations submitted in late June that have not been confirmed. The rate resets: the 8.43 percent bank loan repricing to a floating rate in late 2028 on a business generating $6 to $7 million of annual operating cash flow. And this remains a sub-ten-cent OTC microcap with no analyst coverage, 403 million shares out, and real dilution risk if any of the above forces a raise.
7. The Bottom Line
We came into this quarter asking whether the medical rescheduling would show up. It did, and it was $786,000, against a $2.0 million tax charge on a $1.6 million loss. The more useful finding is the one the sector narrative keeps getting backwards. MariMed is not a company being bled dry by paying 280E. It has been charged $16.4 million over the last ten quarters and paid $130,000. The tax it does not pay has become $31.5 million of interest-free-looking financing, larger at times than the whole company, and that float is a real part of why a business with a $2.8 million operating loss last year is still standing. What changed this quarter is that the float stopped being free: the bank wrote a $100,000-a-month escrow into the loan agreement, and MariMed now funds the disputed tax on a five-year schedule whether or not the IRS ever wins. The framework from here is unchanged in structure and sharper in detail. The status quo is roughly priced once you count the liability. Medical relief is a rounding error for an adult-use operator. The broad Schedule III order is still the only thing that changes the arithmetic, and the DEA process that decides it runs into late 2026 or 2027. What to watch next: whether the DEA registrations are granted and the $786,000 becomes recurring, whether either CDP hearing resolves, whether the escrow ever gets renegotiated, and whether adjusted EBITDA stabilizes or keeps sliding under record revenue. We are not telling you which way it goes. We are showing you where the money actually moves.
This analysis was built with RoboSystems, direct access to structured SEC filing data for every public company that files. New customers get 50% off your first month with code CANNABIS50. robosystems.ai